Marie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.
Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.
According to Cabanillas, more options for RET, ALK, and BRAF mutations exist. TRK mutations are another rare fusion requiring an inhibitor. Additionally, there are limitations on the 2 currently approved therapies, sorafenib (Nexavar) and lenvatinib (Lenvima).
For some patients, these therapies are too dangerous, according to Cabanillas. For patients who have a predisposition for bleeding, especially bleeding from the tumor VEGF inhibitors may be unsafe as they may increase bleeding risk. There is a need for more tolerable therapies for this patient population.